Kneat.com Inc (KSI-X)
CVE:KSI
4.25
0.19
(4.68%) 1d
Financials
Technical Analysis
Buy, Sell or Hold?
Related posts
Most Anticipated Earnings: NTR-T, ONEX-T and more Canadian Companies Reporting Earnings this Week (Feb 17-21)Weekly 52-Week Low (or 52-Week High): BB-T, AEM-T, DOO-T, TSU-T and More 52-Week Highs and Lows (Jan 29-Feb 04)Weekly 52-Week Low (or 52-Week High): BB-T, AEM-T, DOO-T, TSU-T and More 52-Week Highs and Lows (Jan 29-Feb 04)This summary was created by AI, based on 3 opinions in the last 12 months.
Kneat.com Inc (KSI-X) is a promising $630M healthcare SaaS company specializing in data and document management solutions. Experts highlight the company's impressive sales growth trajectory, evidenced by a 60% increase in annual recurring revenue (ARR), despite not yet being profitable. Analysts express confidence that KSI is on the verge of becoming profitable, thanks to strong free cash flows, a solid balance sheet, and healthy gross margins. The company has successfully established itself with major clients in the pharmaceutical sector, which is crucial for its growth strategy. Overall, Kneat.com is viewed favorably, with analysts bullish on its potential for future growth and profitability in regulated industries requiring validation solutions.
Rare to find a high-quality, small-cap tech company in Canada with good management. High growth. Grew ARR last quarter by 60%, very impressive. Valuation of 7x may seem high by Canadian standards, but not compared to US peers. Targeting regulated industries that need a validation solution. No dividend.
Has the majority of the big-pharma household names as customers. Delivered on what they said they would over the years. Still quite a bit to go. Selling to both new customers and current installed base, a very good sign. Likes the metrics, management, the market, customer base.
They bring validation software to biopharma, and they do it well. The chart is strong. He's been adding shares. Before, they were losing as they invested in R&D, but now they're becoming profitable. He expects margins to expand quickly in coming years. When they win a client, it takes time to roll out that client. Growth is safe.
Software company that is based in Ireland.
Offers compliance and validation software in life sciences business.
Currently has 8/10 of top pharma & 18/20 top bio-pharma companies as customers.
Growing customer base at a rapid rate.
Very positive on outlook of business.
Will continue to own shares.
- «
- ‹
- 1
- ›
- »
Kneat.com Inc(KSI-X) Rating
Ranking : 4 out of 5
Bullish - Buy Signals / Votes : 2
Neutral - Hold Signals / Votes : 0
Bearish - Sell Signals / Votes : 0
Total Signals / Votes : 2
Kneat.com Inc(KSI-X) Frequently Asked Questions
What is Kneat.com Inc stock symbol?
Kneat.com Inc is a Canadian stock, trading under the symbol KSI-X on the TSX Venture Exchange (KSI-CV). It is usually referred to as TSXV:KSI or KSI-X
Is Kneat.com Inc a buy or a sell?
In the last year, 2 stock analysts published opinions about KSI-X. 2 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Kneat.com Inc.
Is Kneat.com Inc a good investment or a top pick?
Kneat.com Inc was recommended as a Top Pick by on . Read the latest stock experts ratings for Kneat.com Inc.
Why is Kneat.com Inc stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
Is Kneat.com Inc worth watching?
2 stock analysts on Stockchase covered Kneat.com Inc In the last year. It is a trending stock that is worth watching.
What is Kneat.com Inc stock price?
On 2021-11-12, Kneat.com Inc (KSI-X) stock closed at a price of $4.25.
We like KSI, and we even covered the name in one of our latest podcast episodes (link to our discussion on KSI can be found here).
KSI is a $630M healthcare SaaS company that provides solutions for data and document management. Good sales growth is expected over the next few years, although it is not yet profitable. It generates positive free cash flows, has a strong balance sheet, strong gross margins, and we feel it is at the turning point of becoming profitable. Overall, we like the name and have it in our Growth model portfolio.
Unlock Premium - Try 5i Free